Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Katja Weisel et al.|The Lancet Oncology|2019Cited by 383
The outcome of COVID‐19 in patients with hematological malignancyTuğçe Nur Yiğenoğlu, Şuayıp Birinci, Naim Ata et al.|Journal of Medical Virology|2020Cited by 134
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitorsSemih Başçı, Naim Ata, Fevzi Altuntaş et al.|Journal of Oncology Pharmacy Practice|2020Cited by 40
COVID-19 in hematopoietic cell transplant recipientsŞuayıp Birinci, Fevzi Altuntaş, Naim Ata et al.|Bone Marrow Transplantation|2020Cited by 31
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancersSemih Başçı, Naim Ata, Fevzi Altuntaş et al.|Internal and Emergency Medicine|2021Cited by 19